{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-035203","form_type":"8-K","ticker":"ORIC","cik":"0001796280","company_name":"Oric Pharmaceuticals, Inc.","filed_at":"2025-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.905445+00:00","generated_at":"2026-05-26T04:52:32.544740+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ORIC updates registrational plans for lead drugs, extends cash runway into 2027","bullets":["ORIC-944 first Phase 3 trial in mCRPC expected 1H 2026; combination dose escalation data in 1H and 2H 2025.","ORIC-114 registrational focus on 1L NSCLC with Phase 3 trials planned 2026; 2L/2L+ registration deprioritized.","Comprehensive NSCLC data update expected 2H 2025 including 1L EGFR exon 20 and atypical cohorts.","Cash, cash equivalents and investments totaled $256M as of Dec 31, 2024; projected runway extended into 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-035203","json":"https://secwatch.observer/filing/0001193125-25-035203.json","markdown":"https://secwatch.observer/filing/0001193125-25-035203.md","text":"https://secwatch.observer/filing/0001193125-25-035203.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1796280/000119312525035203/0001193125-25-035203-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1796280/000119312525035203/d830999d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T04:52:32.544740+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}